Formerly the chief scientific officer for Shanghai CP Guojian Pharma, one of China's leading biosimilars manufacturers, Wu Chengbin now leads the biologics startup EpimAb Biotherapeutics. The venture’s development focus is on immuno-oncology candidates and broad collaborations with both China-based companies and multinationals.
In late May, EpiMab announced a deal with Wuxi Biologics, a biological subsidiary of WuXi AppTec Inc., to collaborate towards an investigational new drug filling for EpimAb's first candidate EMB-01
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?